Baricitinib for stubborn non-infectious eye inflammation
Treatments studied
Part of Eyes & vision clinical trials.
This Phase 3 trial tests baricitinib (a medication that calms a specific immune pathway) for people with non-infectious uveitis that has not improved with prior biologic treatments. It also looks at side effects and how well vision and eye inflammation respond when other medicines are stopped before starting the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-infectious uveitis that is not only in the front of the eye
- Your uveitis has not responded to at least one biologic treatment (anti-TNF or tocilizumab)
- You can safely stop biologic and usual anti-inflammatory “immunosuppressant” medicines at least 10 days before starting
- You have not had treatment with a JAK inhibitor before
- You do not have an active eye infection causing the uveitis
- You do not have major vision-threatening flare needing emergency IV steroid treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This trial tests a combination of two medications (adalimumab and mycophenolate mofetil) to reduce eye inflammation in people with uveitis that requires steroids. It aims to help patients use less steroid medication while keeping their uveitis under control.
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
Hear when a new Active Non-anterior Non-infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.